Literature DB >> 23159387

CD24 expression is associated with progression of gastric cancer.

Masakazu Takahashi, Masanobu Nakajima, Hideo Ogata, Yasushi Domeki, Kichiro Ohtsuka, Keisuke Ihara, Eigo Kurayama, Satoru Yamaguchi, Kinro Sasaki, Kazuto Miyachi, Hiroyuki Kato.   

Abstract

BACKGROUND/AIMS: Mortality rates due to gastric cancer are high in Japan. To improve patient prognosis, new biomarkers for diagnosis and treatment are urgently required. In this study we investigated the role of CD24, a cell adhesion glycoprotein implicated in tumor cell proliferation, which is used as a prognostic marker in various cancers.
METHODOLOGY: We analyzed CD24 expression in 173 gastric adenocarcinomas by immunohistochemistry and compared the data with clinicopathological parameters and patient overall survival. Furthermore, we performed Western blotting analysis of CD24 in six human gastric adenocarcinoma cell lines, Kato III, MKN1, MKN28, MKN45, MKN74, and HGC-27.
RESULTS: CD24 up-regulation was significantly correlated with depth of invasion (p=0.005) and pathological high stages (p=0.043). We observed a relationship between high CD24 expression and lymph node metastasis, venous invasion and lymphatic invasion. CD24 expression tended to be higher in cell lines derived from differentiated gastric carcinoma, including those derived from lymph node metastasis.
CONCLUSIONS: Our study suggests that gastric cancer patients with high CD24 expression should be closely monitored for recurrence following resections. CD24 expression is a potential biomarker for gastric cancer prognosis and provides a new molecular target for therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159387     DOI: 10.5754/hge12763

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  CD24 genetic variants contribute to overall survival in patients with gastric cancer.

Authors:  Zhi-Fang Jia; Li-Zhong Wang; Xue-Yuan Cao; Chuan Wang; Dong-Hui Cao; Xing Wu; Li-Li You; Mei-Shan Jin; Yin-Ping Wang; Bao-Sen Zhou; Jing Jiang
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

2.  Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: a meta-analysis.

Authors:  Jing-Xun Wu; Yuan-Yuan Zhao; Xuan Wu; Han-Xiang An
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

3.  Combined aberrant expression of N-Myc downstream-regulated gene 2 and CD24 is associated with disease-free survival and overall survival in patients with hepatocellular carcinoma.

Authors:  Bing Li; Qing Shao; Dong Ji; Fan Li; Xiaodong Guo; Guofeng Chen
Journal:  Diagn Pathol       Date:  2014-10-23       Impact factor: 2.644

4.  Downregulation of CD24 suppresses bone metastasis of lung cancer.

Authors:  Hinako Okabe; Katsuhiko Aoki; Satomi Yogosawa; Mitsuru Saito; Keishi Marumo; Kiyotsugu Yoshida
Journal:  Cancer Sci       Date:  2017-11-29       Impact factor: 6.716

5.  Prognosis genes in gastric adenocarcinoma identified by cross talk genes in disease‑related pathways.

Authors:  Lizhi Zhao; Haichun Lei; Li Shen; Jiquan Tang; Zhiwei Wang; Weisong Bai; Feng Zhang; Shouli Wang; Weihua Li
Journal:  Mol Med Rep       Date:  2017-06-06       Impact factor: 2.952

6.  CD44 but not CD24 expression is related to poor prognosis in non-cardia adenocarcinoma of the stomach.

Authors:  Xueyuan Cao; Donghui Cao; MeiShan Jin; Zhifang Jia; Fei Kong; Hongxi Ma; Yinping Wang; Jing Jiang
Journal:  BMC Gastroenterol       Date:  2014-09-12       Impact factor: 3.067

7.  CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells.

Authors:  Wenjie Deng; Luo Gu; Xiaojie Li; Jianchao Zheng; Yujie Zhang; Biao Duan; Jie Cui; Jing Dong; Jun Du
Journal:  J Transl Med       Date:  2016-02-01       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.